{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:52:04Z","timestamp":1791348724520,"version":"4.3.1"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012669","name":"Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acquired reactive perforating collagenosis (ARPC) is a rare perforating dermatosis characterized by transepidermal elimination of degenerated collagen fibers. It frequently develops secondary to systemic comorbidities, including diabetes mellitus, chronic kidney disease (CKD), and atopic dermatitis (AD), which limit therapeutic options and contribute to unpredictable outcomes. Here, we report a case of ARPC with concurrent AD in a patient with type 2 diabetes mellitus and stage 4 CKD, who experienced acute paradoxical exacerbation within 24\u2005h of dupilumab initiation and achieved sustained remission with upadacitinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>A 72-year-old male presented with a 5-year history of recurrent generalized pruritus, erythema, papules, and nodules. Despite treatment with glucocorticoids and anti-allergic medications, the skin lesions remained poorly controlled. Histopathological examination revealed transepidermal elimination of collagen fibers through the ulcer bed into the underlying dermis. Verhoeff-van Gieson staining demonstrated collagen fibers traversing the ulceration. The patient was diagnosed with ARPC. He had poorly controlled comorbidities, including AD, type 2 diabetes mellitus, and stage 4 CKD. Dupilumab was administered as a single 600\u2005mg dose but was discontinued due to paradoxical worsening within 24\u2005h. Following two years of recurrent relapses despite systemic corticosteroids, antihistamines, and thalidomide, oral upadacitinib 15\u2005mg once daily was initiated, with marked resolution of skin lesions and pruritus. After 9 months of treatment, upadacitinib was discontinued, and the patient remained in stable remission at 1-year follow-up. No adverse effects were observed, and renal function remained stable throughout treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case suggests that upadacitinib is a promising salvage therapy for refractory ARPC, particularly after failure of Th2-targeted biologics. Its favorable safety profile at the standard dose without adjustment in stage 4 CKD supports its use in patients with complex comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1924464","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:48:57Z","timestamp":1791348537000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Upadacitinib in refractory acquired reactive perforating collagenosis with atopic dermatitis and chronic kidney disease: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Qing","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maolin","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"College of Traditional Chinese Medicine, Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lvyao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Suining Municipal Hospital of Traditional Chinese Medicine","place":["Suining, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Qiu","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfang","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1046\/j.1365-2133.2001.04309.x","article-title":"Acquired perforating collagenosis: is it due to damage by scratching?","volume":"145","author":"Thiele-Ochel","year":"2001","journal-title":"Br J Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1111\/jdv.14220","article-title":"Acquired perforating dermatosis: clinicopathological study of 31 cases, emphasizing pathogenesis and treatment","volume":"31","author":"Garc\u00eda-Malinis","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3390\/jcm15010391","article-title":"Acquired reactive perforating collagenosis-A rare entity occurring within common disorders: a systematic review and our personal experience","volume":"15","author":"Junghetu","year":"2026","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1240262","DOI":"10.3389\/fimmu.2023.1240262","article-title":"Dupilumab improve acquired reactive perforating collagenosis characterized by type 2 inflammation","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.2147\/CCID.S549157","article-title":"Efficacy of upadacitinib in the treatment of acquired reactive perforating collagenosis in a patient with type 1 diabetes: a case report and A literature review","volume":"18","author":"Chen","year":"2025","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3969\/j.issn.1674-8468.2023.02.005","article-title":"A comparative study of three diagnostic criteria for atopic dermatitis","volume":"30","author":"Zhao","year":"2023","journal-title":"Diagn Ther J Dermato-Venereol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.3390\/biomedicines10112700","article-title":"A systematic review of atopic dermatitis: the intriguing journey starting from physiopathology to treatment, from laboratory bench to bedside","volume":"10","author":"Radi","year":"2022","journal-title":"Biomedicines"},{"key":"B8","doi-asserted-by":"publisher","first-page":"6265608","DOI":"10.1155\/2024\/6265608","article-title":"Successful use of dupilumab in the treatment of acquired perforating dermatosis associated with atopic dermatitis","volume":"2024","author":"Gori","year":"2024","journal-title":"Case Rep Dermatol Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/14740338.2024.2326480","article-title":"Dupilumab in real-life settings: a review of adverse events and their pathogenesis","volume":"23","author":"Camela","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"B10","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3390\/biom12040542","article-title":"Advanced glycation end products and diabetes mellitus: mechanisms and perspectives","volume":"12","author":"Khalid","year":"2022","journal-title":"Biomolecules"},{"key":"B11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3390\/toxins12050300","article-title":"Chronic kidney disease-associated immune dysfunctions: impact of protein-bound uremic retention solutes on immune cells","volume":"12","author":"Espi","year":"2020","journal-title":"Toxins (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/jcph.1375","article-title":"Characterization of the effect of renal impairment on upadacitinib pharmacokinetics","volume":"59","author":"Mohamed","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jdcr.2024.04.017","article-title":"A potential new treatment with upadacitinib for acquired reactive perforating collagenosis","volume":"48","author":"Ding","year":"2024","journal-title":"JAAD Case Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1388274","DOI":"10.3389\/fimmu.2024.1388274","article-title":"Effectiveness of baricitinib in acquired reactive perforating collagenosis: a case report","volume":"15","author":"Zheng","year":"2024","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1001\/jamadermatol.2024.6280","article-title":"Tofacitinib for treatment of acquired reactive perforating collagenosis","volume":"161","author":"Yuan","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/ced\/llaf122","article-title":"A unique case of reactive perforating collagenosis secondary to upadacitinib treatment of severe atopic eczema","volume":"50","author":"Morrison","year":"2025","journal-title":"Clin Exp Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1924464\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:49:07Z","timestamp":1791348547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1924464\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":18,"alternative-id":["10.3389\/fmed.2026.1924464"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1924464","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1924464"}}